LianBio (LIANY)

Market Cap	13.20M -59.2%
Revenue (ttm)	n/a
Net Income	-87.98M
EPS	-0.82
Shares Out	108.17M
PE Ratio	n/a
Forward PE	n/a
Dividend	0.38 (311.48%)
Ex-Dividend Date	Jul 15, 2025

Volume	800
Average Volume	93,606
Open	0.1220
Previous Close	n/a
Day's Range	0.1220 - 0.1220
52-Week Range	0.0300 - 0.4394
Beta	0.10
RSI	46.99
Earnings Date	n/a

About LianBio

LianBio, operates as a biotechnology company in China and other Asian countries. It offers medicines for cardiovascular, oncology, ophthalmology, and inflammatory disease indications. The company develops mavacamten for the treatment of obstructive hypertrophic cardiomyopathy, which is in Phase 3 EXPLORER-CN trial; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease, which is in Phase 3 LIBRA trial; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of FGFR2 ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2019
• Employees: 163
• Stock Exchange: OTCMKTS
• Ticker Symbol: LIANY